3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with clozapine in 13 studies
| Studies (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Trials (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Recent Studies (post-2010) (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Studies (clozapine) | Trials (clozapine) | Recent Studies (post-2010) (clozapine) |
|---|---|---|---|---|---|
| 330 | 40 | 33 | 9,691 | 747 | 3,148 |
| Protein | Taxonomy | 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide (IC50) | clozapine (IC50) |
|---|---|---|---|
| Adenylate cyclase type 1 | Rattus norvegicus (Norway rat) | 0.14 | |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 3.6 | |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.032 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 1.47 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.476 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.045 | |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.1233 | |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.1534 | |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.1534 | |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.15 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.031 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.1534 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.013 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.09 | |
| Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | 0.14 | |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.1534 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0096 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 2 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.2044 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0886 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.023 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0079 | |
| D | Rattus norvegicus (Norway rat) | 1.066 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.2695 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
| D(2) dopamine receptor | Bos taurus (cattle) | 1.804 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.078 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.107 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.0796 | |
| Adenylate cyclase type 3 | Rattus norvegicus (Norway rat) | 0.14 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 1.47 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 5.7544 | |
| Histamine H2 receptor | Homo sapiens (human) | 3.61 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.035 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
| Adenylate cyclase type 2 | Rattus norvegicus (Norway rat) | 0.14 | |
| Adenylate cyclase type 4 | Rattus norvegicus (Norway rat) | 0.14 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0658 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0658 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.373 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.587 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.587 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0338 | |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.023 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.546 | |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.028 | |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.028 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.0049 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.354 | |
| Adenylate cyclase type 8 | Rattus norvegicus (Norway rat) | 0.14 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.081 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.0171 | |
| D(2) dopamine receptor | Mus musculus (house mouse) | 0.29 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.6759 | |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 3.6 | |
| 5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.028 | |
| Adenylate cyclase type 6 | Rattus norvegicus (Norway rat) | 0.14 | |
| Adenylate cyclase type 5 | Rattus norvegicus (Norway rat) | 0.14 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4162 | |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 3.6 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 3.6 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 2 | |
| Adenylyl cyclase 7 | Rattus norvegicus (Norway rat) | 0.14 | |
| D | Bos taurus (cattle) | 4.09 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (84.62) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Esch, IJ; Fratantoni, SA; Hulscher, S; Hulshof, JW; Leurs, R; Smit, MJ; Verheij, MH; Victorina, J; Vischer, HF | 1 |
| Costa, DC; Ell, PJ; Kerwin, RW; Murray, RM; Pilowsky, LS; Verhoeff, NP | 1 |
| Bockisch, A; Hahn, K; Hiemke, C; Nickel, O; Schlegel, S; Schlösser, R | 1 |
| Bartko, JJ; Breier, A; Coppola, R; Gorey, J; Hsiao, J; Knable, MB; Lee, KS; Malhotra, AK; Pickar, D; Su, TP; Weinberger, DR | 1 |
| Breier, A; Hadd, K; Malhotra, AK; Pickar, D; Su, TP | 1 |
| Bockisch, A; Hahn, K; Hiemke, C; Nickel, O; Rao, ML; Schlegel, S; Schlösser, R | 1 |
| Asenbaum, S; Brücke, T; Kasper, S; Küfferle, B; Podreka, I; Tauscher, J; Vesely, C | 1 |
| Asenbaum, S; Barnas, C; Brücke, T; Hesselmann, B; Kasper, S; Küfferle, B; Podreka, I; Tauscher, J | 1 |
| Dähne, I; Dresel, S; Hahn, K; Mager, T; Scherer, J; Tatsch, K | 1 |
| Biersack, HJ; Broich, K; Grünwald, F; Kasper, S; Klemm, E; Möller, HJ | 1 |
| Asenbaum, S; Barnas, C; Brücke, T; Fischer, P; Kasper, S; Küfferle, B; Pezawas, L; Tauscher, J; Tauscher-Wisniewski, S | 1 |
| Seeman, P; Tallerico, T | 1 |
| Gertz, HJ; Hohdorf, K; Künstler, U; Regenthal, R; Seese, A | 1 |
3 trial(s) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and clozapine
| Article | Year |
|---|---|
IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzamides; Clozapine; Dibenzothiazepines; Dopamine Antagonists; Female; Haloperidol; Humans; Male; Middle Aged; Neostriatum; Psychotic Disorders; Pyrrolidines; Quetiapine Fumarate; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1997 |
D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Clozapine; Dose-Response Relationship, Drug; Female; Frontal Lobe; Humans; Male; Neostriatum; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1998 |
In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzamides; Benzodiazepines; Clozapine; Contrast Media; Corpus Striatum; Female; Haloperidol; Humans; Iodine Radioisotopes; Male; Middle Aged; Olanzapine; Pirenzepine; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 1999 |
10 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and clozapine
| Article | Year |
|---|---|
Identification of novel allosteric nonpeptidergic inhibitors of the human cytomegalovirus-encoded chemokine receptor US28.
Topics: Amines; Humans; Imipramine; Indenes; Ligands; Molecular Structure; Receptors, Chemokine; Structure-Activity Relationship; Viral Proteins | 2010 |
Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzamides; Brain; Clozapine; Computers; Female; Humans; Male; Psychiatric Status Rating Scales; Pyrrolidines; Receptors, Dopamine; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1992 |
Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT.
Topics: Adult; Antipsychotic Agents; Benperidol; Benzamides; Clozapine; Corpus Striatum; Dopamine Antagonists; Haloperidol; Humans; Iodine Radioisotopes; Male; Middle Aged; Prolactin; Prosencephalon; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia, Paranoid; Tomography, Emission-Computed, Single-Photon | 1996 |
Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients.
Topics: Adult; Benzamides; Binding, Competitive; Clozapine; Corpus Striatum; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 1996 |
D2 dopamine receptor occupancy: a crossover comparison of risperidone with clozapine therapy in schizophrenic patients.
Topics: Adult; Benzamides; Clozapine; Humans; Iodine Radioisotopes; Male; Middle Aged; Psychiatric Status Rating Scales; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia | 1997 |
[123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benperidol; Benzamides; Bipolar Disorder; Brain; Clozapine; Corpus Striatum; Depressive Disorder, Major; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Frontal Lobe; Haloperidol; Humans; Male; Middle Aged; Neurologic Examination; Psychiatric Status Rating Scales; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia, Paranoid; Tomography, Emission-Computed, Single-Photon | 1997 |
Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study.
Topics: Adult; Antipsychotic Agents; Benzamides; Clozapine; Female; Haloperidol; Humans; Imidazoles; Indoles; Iodine Radioisotopes; Male; Middle Aged; Neostriatum; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1998 |
Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Brain; Clozapine; Contrast Media; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Iodine Radioisotopes; Male; Middle Aged; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1998 |
Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.
Topics: Animals; Antipsychotic Agents; Benzamides; Brain; Carbon Radioisotopes; Cloning, Molecular; Clozapine; Dibenzothiazepines; Dopamine; Dose-Response Relationship, Drug; Humans; Iodine Radioisotopes; Mice; Pyrrolidines; Quetiapine Fumarate; Raclopride; Radionuclide Imaging; Receptors, Dopamine D2; Salicylamides; Spodoptera; Substance Withdrawal Syndrome; Tritium | 1999 |
[Diminution of hand writing area and D2-dopamine receptor blockade. Results from treatment with typical and atypical neuroleptics].
Topics: Adult; Aged; Antipsychotic Agents; Benzamides; Clozapine; Dopamine Antagonists; Female; Haloperidol; Handwriting; Humans; Male; Middle Aged; Neostriatum; Pyrrolidines; Receptors, Dopamine; Risperidone; Schizophrenia, Paranoid; Therapeutic Equivalency; Tomography, Emission-Computed, Single-Photon | 2000 |